MLTX

MoonLake Immunotherapeutics

• TipRanks·5d ago

  Major Insider Move at MoonLake Immunotherapeutics Shakes Up Investor Sentiment

• Reuters·5d ago

  BVF Partners reports MoonLake Immunotherapeutics share sale worth $63.33 million

• TipRanks·03/31 17:00

  Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA), Apellis Pharmaceuticals (APLS) and MoonLake Immunotherapeutics (MLTX)

• TipRanks·03/31 11:50

  Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Neumora Therapeutics, Inc. (NMRA) and Aurinia Pharmaceuticals (AUPH)

• Benzinga·03/30 15:27

  MoonLake Says Lead Drug Shows Durable Response, Eyes FDA Filing

• Dow Jones·03/30 12:52

  MoonLake Immunotherap Price Target Maintained With a $30.00/Share by BTIG

• Benzinga·03/30 12:43

  BTIG Reiterates Buy on MoonLake, Maintains $30 Price Target

• TipRanks·03/30 11:02

  Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), AbSci (ABSI) and MaxCyte (MXCT)

• TipRanks·03/30 10:36

  H.C. Wainwright Keeps Their Buy Rating on MoonLake Immunotherapeutics (MLTX)

• NASDAQ·03/30 08:27

  MoonLake's Sonelokimab Shows Strong Week 40 Results With 62% Achieving HiSCR75

• Benzinga·03/30 06:53

  Reported Saturday, MoonLake's Phase 3 VELA Trials Show Sonelokimab Achieves 62% HiSCR75 And Up To 32% HiSCR100 At Week 40 In Moderate-To-Severe Hidradenitis Suppurativa

• TipRanks·03/29 14:35

  MoonLake Immunotherapeutics announces results from Phase 3 VELA-1, VELA-2 trial

• Reuters·03/28 19:00

  MoonLake sonelokimab hits 62% HiSCR75 at Week 40 in Phase 3 HS trials

• TipRanks·03/26 17:25

  MoonLake Immunotherapeutics management to meet with BTIG

• Benzinga·03/23 15:22

  This APA Analyst Is No Longer Bearish; Here Are Top 2 Upgrades For Monday